Reviva Pharmaceuticals -CW23RVPHWPreferred / convertible
13F holders, Q3 2025 (September 30)2holders −1
1new positions
1sold out
$0.08avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Reviva Pharmaceuticals -CW23 (RVPHW) in their 13F filings, down 1 from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($11K) and Virtu Financial LLC ($2K).
- Company
- Reviva Pharmaceuticals -CW23
- Filed as
- EVIVA PHARMACEUTCLS HLDGS I (Q3 2025)
- CUSIP
- 76152G118
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 1 | $3 |
All 13F filers, Q2 2025 → Q3 2025: 139,850 shares bought and 100 shares sold, net +139,750 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Susquehanna International Group, LLP | — | Add +785.9% | 134,668 | $11K |
| Virtu Financial LLC | — | New | 20,383 | $2K |
"% of holder's portfolio" is RVPHW's weight in each manager's 13F, not the share of Reviva Pharmaceuticals -CW23 the manager owns.